Researchers develop light-activated Parkinson’s drug

News

Author: Simge Eva DoganPublished: 18 July 2018

Prep: Cook: Serves:

A new light-activated drug for treating Parkinson’s has been developed by a research team led by the University of Barcelona, Spain.

The drug – named MRS7145 – is placed within a brain implant and then activated by shining a light on it.

The effect of the newly developed drug was tested on live mice to see if it could improve their motor function. The results – published in ‘Journal of Controlled Release’ – showed that MRS7145 reduced tremors and seizures and improved the mice’s ability to walk.

Professor Francisco Ciruela, researcher at the Faculty of Medicine and Health Sciences of the University of Barcelona, Spain, said he envisaged the drug being administered by smart phones, with “the doctor (controlling) in a precise manner the release of the most efficient dose of the active drug in the place of action”.

For more information on Parkinson’s research please visit Parkinson’s Europe website.

Last Month

Next Month

Go Back

Share this story

Comments

Interviews

“With Parkinson’s disease, rhythm can help you walk and singing can help you speak”

We hear from Parkinsong founder Gerald Ganglbauer

John McLean: Parkinson’s has exposed me to new painting techniques

The abstract painter tells us about his Cure3 Exhibition art

#UniteForParkinsons: the story so far

Highlights from #UniteForParkinsons 2017

Parkinson’s Europe co-founder Lizzie Graham wins World Parkinson Coalition award

Parkinson’s Europe co-founder Lizzie Graham has won a World Parkinson Coalition (WPC) award for her contribution to the Parkinson’s community. Lizzie is one of four people set to receive the Robin Elliott Award – which is given out every three years to individuals whose efforts best embody the goals and ethos of the WPC. She will be presented with the award in a ceremony at the World Parkinson’s Congress, which will be held in Barcelona later this year. Commenting on the news of Lizzie’s award, Parkinson’s Europe President, Veronica Clark, said: “Lizzie is Lizzie, and we love her for who she is and what she has done for us all – for people with Parkinson’s past and present and, I’m sure, future.” Lizzie co-founded the European Parkinson’s Disease Association (renamed Parkinson’s Europe last year) in 1992. She has since held several roles within the organisation – including secretary general and…

Study explores predictors of cognitive impairment in Parkinson’s disease

Cognitive impairment can affect some people with Parkinson’s – and may greatly impact their quality of life. Now, researchers in China have examined the possible risk factors for cognitive impairment in those with the condition. The study analysed data from 409 people with Parkinson’s within two years of their involvement in the Parkinson’s Progression Markers Initiative (PPMI) – an international study that follows people with and without the condition over time. The participants, who were newly diagnosed and experiencing normal cognitive function at the start of the research, were studied for at least five years. Published in ‘Frontiers in Aging Neuroscience’, the results indicate that older age at onset, high blood pressure and worse baseline motor symptoms may be among factors that could contribute to an increased risk of developing cognitive impairment. The researchers cautioned that “a larger sample and much more comprehensive assessment, and prolonged follow-up, will be required”.

Could frailty be a potential risk factor for Parkinson’s disease?

Frailty can refer to a reduction in physical function, and its attributes – including a slow walking speed and weak grip – are commonly experienced by people with Parkinson’s. Until now, there has been limited insight into the link between frailty and the risk of developing the condition over time. This is what led researchers at the Huazhong University of Science and Technology in China to analyse data from a large UK study, which was gathered over a 12-year period. Published in JAMA Neurology, the analysis found that frailty may be linked to an 87% higher risk of developing the condition. Commenting on the results, the researchers said: “These findings indicate that physical frailty is a potential risk factor for [Parkinson’s], and the assessment and management of frailty might have clinical significance in the at-risk population.”

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Comments
This field is for validation purposes and should be left unchanged.

Researchers develop light-activated Parkinson’s drug

News

Author: Simge Eva DoganPublished: 18 July 2018

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Interviews

“With Parkinson’s disease, rhythm can help you walk and singing can help you speak”

Interviews

John McLean: Parkinson’s has exposed me to new painting techniques

Global update

#UniteForParkinsons: the story so far

Parkinson’s Europe co-founder Lizzie Graham wins World Parkinson Coalition award

Study explores predictors of cognitive impairment in Parkinson’s disease

Could frailty be a potential risk factor for Parkinson’s disease?

{title}

Subscribe

Researchers develop light-activated Parkinson’s drug

News

Author: Simge Eva DoganPublished: 18 July 2018

Last Month

Next Month

Share this story

Comments

Related articles

Interviews

“With Parkinson’s disease, rhythm can help you walk and singing can help you speak”

Interviews

John McLean: Parkinson’s has exposed me to new painting techniques

Global update

#UniteForParkinsons: the story so far

Parkinson’s Europe co-founder Lizzie Graham wins World Parkinson Coalition award

Study explores predictors of cognitive impairment in Parkinson’s disease

Could frailty be a potential risk factor for Parkinson’s disease?

{title}

Subscribe

Sign in